Takeda Pharmaceutical Company Limited American Depositary Share — Financial Statistics (NYSE:TAK) | MetaTrader

Open full chart

News

Takeda Remains A Buy, Boosted By Recent Narcolepsy Drug Approval And Robust Pipeline

Takeda Presents Phase 3 Data Showing Once-Daily Oral Zasocitinib Delivers Higher PASI 100 At 36.5% Vs 13.9% And PASI 90 At 62.5% Vs 34.0% Than Deucravacitinib At Week 16; Under FDA, EMA Review For Plaque Psoriasis

KROS Begins Dosing in Phase II Study With Rinvatercept in DMD

Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial

This Cancer Drug Is Already Working. Now Its Nvidia-Backed Maker Is Going Public: Here’s What You Need to Know About Its IPO

Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?

5 Undervalued Oncology Stocks Wall Street Is Overlooking (NASDAQ:IBB)

Best Value Stocks to Buy for September 14th

Best Income Stocks to Buy for September 14th

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

Exelixis: 'Hold' On Zanzalintinib Subpopulation Miss And STELLAR-304 H2 2026 Data

Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know